Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Ryukaikon Resumes Discussions
July 3, 2006
- Concern Expressed about Qualifications of New "Registered Drug Sellers"
July 3, 2006
- REGULATORY NEWS IN BRIEF
July 3, 2006
- Sales of OTC Smoking Cessation Aids to Grow in 2006: Fuji Keizai
July 3, 2006
- Indications of Generics to Be Brought in Line with Those of Original Products
July 3, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 3, 2006
- 7 Complaints Received Regarding Supply of Generics: EAD
July 3, 2006
- Shionogi to Develop In-House Products Overseas Through PIIb: Dr Teshirogi
July 3, 2006
- Original Makers Suspected of Obstructing Generic Houses' Business: JFTC
July 3, 2006
- SURVEY 3 articles
July 3, 2006
- Generic Makers Concerned about Extension of Data Protection Period: IGPA Conference
July 3, 2006
- Epadel, Atelec Continue to Drive Mochida's Business
July 3, 2006
- 66th Annual Scientific Sessions of the American Diabetes Association
July 3, 2006
- Blopress Retained Rank as Top-selling Drug in FY2005
July 3, 2006
- Pediatric Clinical Trial of Ketek Temporarily Discontinued in US: sanofi-aventis
July 3, 2006
- COMMENTARY 3 atricles
July 3, 2006
- Toyama Chemical Initiates PI Trial of Anti-RA Drug T-5224
July 3, 2006
- Average Wage Hike in Pharma Industry Higher Than All-Industry Average: Survey
July 3, 2006
- Bayer Initiates PIII for Antithrombosis Drug Rivaroxaban
July 3, 2006
- Bayer Succeeds in Taking Over Schering AG
July 3, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…